1. Home
  2. XRAY vs MESO Comparison

XRAY vs MESO Comparison

Compare XRAY & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DENTSPLY SIRONA Inc.

XRAY

DENTSPLY SIRONA Inc.

HOLD

Current Price

$11.70

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$15.24

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XRAY
MESO
Founded
1899
2004
Country
United States
Australia
Employees
N/A
81
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.1B
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
XRAY
MESO
Price
$11.70
$15.24
Analyst Decision
Hold
Strong Buy
Analyst Count
14
1
Target Price
$14.58
N/A
AVG Volume (30 Days)
3.0M
208.0K
Earning Date
05-05-2026
02-26-2026
Dividend Yield
5.43%
N/A
EPS Growth
33.04
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$629.74
Revenue Next Year
$2.06
$30.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.85
$9.88
52 Week High
$17.18
$21.50

Technical Indicators

Market Signals
Indicator
XRAY
MESO
Relative Strength Index (RSI) 44.80 48.19
Support Level $10.96 $14.44
Resistance Level $12.28 $16.49
Average True Range (ATR) 0.44 0.43
MACD -0.01 0.01
Stochastic Oscillator 13.91 39.08

Price Performance

Historical Comparison
XRAY
MESO

About XRAY DENTSPLY SIRONA Inc.

Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is sold to labs and offices through the firm's salesforce or directly to consumers (such as the Byte clear aligner).

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: